VAXINIA MAST Trial Clears Intratumoral Combination Cohort 1

The multicenter Phase 1 MAST trial commenced by delivering a low dose of VAXINIA to patients with metastatic or advanced solid tumours who have had at least two prior lines of standard of care treatment. The City of Hope-developed oncolytic virus has been shown laboratory and animal models¹. Overall, the study aims to recruit up to 100 patients across approximately 10 trial sites in the United Sta